Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/liv.70263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multimodal treatment approach with sunitinib, pembrolizumab, bevacizumab, sirolimus, and zoledronic acid for locally advanced clear cell renal cell carcinoma: a case report.
Croat Med J
August 2025
Mehrdad Payandeh, Internal Medicine Department, School of Medicine, Kermanshah University of Medical Sciences, Beheshti Blvd, 83VX+PCM, Kermanshah, Iran,
Locally advanced renal cell carcinoma (RCC) presents significant therapeutic challenges, particularly in resource-limited settings with restricted access to new therapies. This report describes a new exploratory multimodal therapeutic approach for a patient with locally advanced clear cell RCC (ccRCC) with adrenal and lymph node metastases. A 45-year-old woman presented with an incidentally discovered 9-cm mass in the left kidney, which was later diagnosed as grade-2 ccRCC with adrenal and lymph node involvement.
View Article and Find Full Text PDFIncidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience.
Front Oncol
August 2025
Department of Radiation Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Introduction: Tyrosine kinase inhibitors (TKIs) are the standard treatment options for advanced clear cell renal cell carcinoma (ccRCC), but their toxicities can hinder optimal dosing, affecting clinical outcomes.
Material And Methods: A retrospective analysis of 96 patients treated with first-line line sunitinib at the National Research Institute of Oncology, Branch Kraków, Poland was conducted to assess the incidence and prevalence of organ toxicities in ccRCC and their impact on overall survival (OS).
Results: The study included 96 patients.
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
September 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:
Background: The underexplored potential of PD-L1 blockade in advanced renal cell carcinoma highlights an urgent need for novel agents. This trial aimed to compare benmelstobart (a novel PD-L1 inhibitor) plus anlotinib with sunitinib as first-line treatment for advanced renal cell carcinoma.
Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial conducted at 37 medical sites in China.
Glutaminase inhibition confers antitumor effects in vitro and in vivo on tyrosine kinase inhibitors-resistant renal cell carcinoma cells by affecting vascular endothelial growth factor signaling.
Biomed Pharmacother
August 2025
Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Tyrosine kinase inhibitors (TKIs) are key drugs in advanced renal cell carcinoma. Their prolonged efficacy is expected to translate directly into improved prognosis for patients with advanced renal cell carcinoma. In our previous studies, we identified important metabolic pathways related to sunitinib resistance.
View Article and Find Full Text PDFLipid-Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma.
Adv Sci (Weinh)
August 2025
Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Renal cell carcinoma (RCC) remains a significant clinical challenge due to delayed diagnosis and multidrug resistance, necessitating innovative strategies to enhance early detection and therapeutic efficacy. This review evaluates the role of lipid-based nanoparticles (LNPs), including liposomes, micelles, nanoemulsions, solid lipid nanoparticles, and nanostructured lipid carriers, as advanced drug delivery systems in providing innovative solutions for RCC diagnosis and treatment. These LNPs exhibit unique advantages of great biocompatibility, biodegradability, extended circulation, and tumor-targeting capabilities, which enable precise drug delivery, controlled release, and circumvention of drug resistance mechanisms.
View Article and Find Full Text PDF